Wave Outlines WVE-007 Phase IIa for Obesity, Projects Cash Runway into Q3 2028

Wave has provided details on its WVE-007 Phase IIa clinical trial for obesity in patients with a BMI of 35-50, and projects its cash runway to extend into the third quarter of 2028.